Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001969764-25-000003
Filing Date
2025-12-23
Accepted
2025-12-23 14:20:47
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 12033
2 JOINDER agr.pdf EX-1 367734
3 ADDITIONALDISCLOSURES addldisc.pdf EX-2 8131
  Complete submission text file 0001969764-25-000003.txt   531692
Mailing Address 1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420 MONTREAL A8 H4M 2X6
Business Address 1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420 MONTREAL A8 H4M 2X6 (514) 336-0444
Milestone Pharmaceuticals Inc. (Subject) CIK: 0001408443 (see all company filings)

EIN.: 000000000 | State of Incorp.: A8 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-91001 | Film No.: 251598498
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 11620 WILSHIRE BLVD., SUITE 350 LOS ANGELES CA 90025
Business Address 11620 WILSHIRE BLVD., SUITE 350 LOS ANGELES CA 90025 908-507-9629
Propel Bio Management, LLC (Filed by) CIK: 0001969764 (see all company filings)

EIN.: 874563546 | Fiscal Year End: 1231
Type: SCHEDULE 13G